Actinium Pharmaceuticals, Inc. (ATNM) Stock Score, Valuation & Financial Research
Actinium Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 50/100.
Quick answer for ATNM
Actinium Pharmaceuticals, Inc. currently has a Wall Street Score of 50/100. The stored market price is $1.24. Its financial score is 12/100. Its valuation score is 100/100. The latest WSS change is -3.5 points. These figures are a research snapshot, not a buy or sell recommendation.
What Actinium Pharmaceuticals, Inc. does
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45,
ATNM financial snapshot
- Wall Street Score:
- 50/100
- Current price:
- $1.24
- Market capitalization:
- $38.9M
- Revenue:
- $35.1M
- Net income:
- $11.3M
- Free cash flow:
- $-24.7M
- Cash:
- $36.5M
- Total debt:
- $1.3M
- EPS:
- 0.36
- P/E ratio:
- 3.4x
- Financial score:
- 12/100
- Valuation score:
- 100/100
- Revenue score:
- 61/100
What stands out
- Reported year-over-year revenue growth is +388.9%.
- Free cash flow is $-24.7M, showing cash burn in the current stored period.
- The balance sheet shows $36.5M of cash versus $1.3M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -3.5 points: ATNM decreased 3.5 points because Asset declined by 3.2 points.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ATNM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.